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Abstract
Enterobacteriaceae that contain the High Pathogenicity Island (HPI), which encodes the siderophore yersiniabactin, display
increased virulence. This increased virulence may be explained by the increased iron scavenging of the bacteria, which
would both enhance bacterial growth and limit the availability of iron to cells of the innate immune system, which require
iron to catalyze the Haber-Weiss reaction that produces hydroxyl radicals. In this study, we show that yersiniabactin
increases bacterial growth when iron-saturated lactoferrin is the main iron source. This suggests that yersiniabactin provides
bacteria with additional iron from saturated lactoferrin during infection. Furthermore, the production of ROS by
polymorphonuclear leukocytes, monocytes, and a mouse macrophage cell line is blocked by yersiniabactin, as
yersiniabactin reduces iron availability to the cells. Importantly, iron functions as a catalyst during the Haber-Weiss
reaction, which generates hydroxyl radicals. While the physiologic role of the Haber-Weiss reaction in the production of
hydroxyl radicals has been controversial, the siderophores yersiniabactin, aerobactin, and deferoxamine and the iron-
chelator deferiprone also reduce ROS production in activated innate immune cells. This suggests that this reaction takes
place under physiological conditions. Of the tested iron chelators, yersiniabactin was the most effective in reducing the ROS
production in the tested innate immune cells. The likely decreased bacterial killing by innate immune cells resulting from
the reduced production of hydroxyl radicals may explain why the HPI-containing Enterobacteriaceae are more virulent. This
model centered on the reduced killing capacity of innate immune cells, which is indirectly caused by yersiniabactin, is in
agreement with the observation that the highly pathogenic group of Yersinia is more lethal than the weakly pathogenic and
the non-pathogenic group.
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Introduction
Yersinia pestis is regarded not only as a potential bioterrorism
threat, but also as a re-emerging pathogen [1]. To combat this
potential threat, understanding the pathogenesis of Yersinia species
is crucial. Yersinia spp. can be divided into a high-pathogenicity
group (Y. pestis, Yersinia pseudotuberculosis, and Yersinia enterocolitica
biogroup 1B), a low-pathogenicity group (Y. enterocolitica biogroups
2 to 5), and a non-pathogenic group (Y. enterocolitica biogroup 1A)
on the basis of the lethal infectious dose in a mouse model [2,3].
Of these groups, only the high-pathogenicity group contains the
High Pathogenicity Island (HPI) [2,3]. This HPI is generally
adjacent to the type III secretion system secreted Yersinia outer
proteins (Yops), an essential factor for the full virulence of Y. pestis
in mammals [4–6]. The HPI was first described in Yersinia spp., but
it has also been described in other Enterobacteriaceae [7–12]. Similar
to Yersinia spp., Escherichia coli and Klebsiella pneumoniae isolates that
contain the HPI are more virulent than isolates that lack the island
[4,12–16]. Furthermore, the HPI was highly associated with an
Enterobacter hormaechei outbreak strain (EHOS) that caused a nation-
wide outbreak in The Netherlands [17–19]. The HPI encodes for
an effective siderophore, yersiniabactin. Yersiniabactin is synthe-
sized by a complex assembly line in which YbtS, YbtE, HMWP1,
HMWP2, and YbtU are essential proteins [20,21]. HMWP1 and
HMWP2 (High Molecular Weight Protein 1 and 2) are 350 and
230 kDa proteins that are encoded by irp1 and irp2, respectively
[22,23]. In addition to these factors, other genes are involved in
the regulation and transport of yersiniabactin, such as the fyuA
gene, which encodes the yersiniabactin receptor.
Yersiniabactin facilitates iron uptake, which is essential for
bacterial growth. In an environment with very limited free iron,
such as the human body, where most iron is bound to proteins,
bacterial expression of the HPI genes has been shown to be
elevated [24,25].
Iron plays an important role in the innate immune system. With
the exception of a very limited amount of free iron, in mammals
most iron is found incorporated into complex molecules, such as
hemin, or bound to transferrin and lactoferrin. During infection,
polymorphonuclear leukocytes (PMNs) upregulate lactoferrin
production, which reduces the availability of free iron for bacteria
and increases the availability of lactoferrin-containing iron for
PMNs [26]. PMNs release the lactoferrin-containing iron into
their phagocytic vacuoles where iron(II) can function as a catalyst
to produce hydroxyl radicals (NOH) from hydrogen peroxide
(H2O2) and superoxide anions (O
–
2) via the Haber-Weiss reaction
[27–29]. Hydroxyl radicals are highly reactive and one of the most
potent oxidants of the reactive oxygen species (ROS) produced by
phagocytic cells [27–29]. However, conclusive evidence that the
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hydroxyl radicals are produced is lacking [30]. The endogenous
production of hydroxyl radicals by PMNs is in doubt because the
specificity of the experiments has been questioned, and it has been
argued that exogenous iron in the buffers used during in vitro
experiments could catalyze the production of hydroxyl radicals
rather than endogenous production in PMNs [31]. Whether
monocytes or monocyte-derived macrophages are also dependent
upon iron provided by lactoferrin for the production of hydroxyl
radicals is unclear, but they are able to produce hydroxyl radicals
when activated, where exogenous Fe(III) can serve as a catalyst
[32,33].
The aim of our study was to investigate the possible role of
yersiniabactin in virulence.
Growth experiments with a wild-type, yersiniabactin-producing
strain (E4) and a yersiniabactin-negative irp2 mutant derived from
E4 were performed to determine which human-derived iron
source was beneficial for the growth of yersiniabactin-producing
bacteria. Eighty percent iron-saturated lactoferrin supported the
growth of the wild-type E4, but not the irp2 mutant. Because the
increased virulence of yersiniabactin-producing bacteria could not
solely be explained by the increased iron uptake and growth, we
hypothesized that yersiniabactin may affect the innate immune
system [10]. Previous work has demonstrated a dual role for
another siderophore, deferoxamine: deferoxamine provided iron
to Y. enterocolitica and modulated the innate immune system
[34,35]. Furthermore, we hypothesized that PMNs use iron for the
production of hydroxyl radicals [28]. Therefore, we speculated
that yersiniabactin may also play a role in reducing the innate
immune response. This hypothesis was investigated by testing the
effect of yersiniabactin and other iron chelators on the ROS
production of activated innate immune cells. Of the tested iron
chelators, ROS production by innate immune cells was most
inhibited by yersiniabactin.
Results
Dual Role for Yersiniabactin
Based on the observed increase in the virulence of HPI-positive
isolates, it has been suggested that in addition to providing iron to
bacteria, the HPI also contributes to the increased virulence of
HPI-containing Enterobacteriaceae. To study the possible role of
yersiniabactin in virulence, a knockout EHOS strain was
successfully constructed. The disruption of the irp2 gene was
verified by DNA sequencing (Accession number: FN421462). A
GFP production assay in which GFP is induced in the presence of
yersiniabactin was used to confirm that the production of
yersiniabactin was disabled in the irp2 knockout. The fluorescence
signal with supernatant from cultures of the irp2 knock-out strain
was low compared to the fluorescence signal obtained with the
supernatant from wild type E4 cultures (Figure 1A). This indicates
that yersiniabactin is produced by the wild-type E4 but not by the
irp2 knock-out isolate. When the supernatant from wild-type
bacterial cultures grown in iron-containing medium was used for
the GFP assay, the production of GFP was not upregulated,
demonstrating that yersiniabactin production is dependent on
iron (Figure 1B). In addition, no production of HMWP1 or
HMWP2, as measured using SPS-PAGE, could be detected in the
irp2 knockout strain cultured in iron-depleted medium
(Figure 1C), while HMWP1 and HMWP2 were expressed in the
wild-type EHOS cultures. The putative HMWP2 band from
EHOS 03-819 was confirmed by Edman degradation sequencing
of the first eight amino acids, which were enough to identify
HMWP2.
The growth of the wild-type E4 and irp2 knockout strains in the
presence of different iron sources was tested. At low iron
concentrations (nutrient broth treated with 1% Chelex), isolate
EHOS E4 demonstrated slightly better growth during the
stationary phase than the irp2 knockout strain (Figure 2A).
Furthermore, the time the wild-type strain remained in the
exponential growth phase was longer, and the plateau of the
stationary phase was significantly higher (p,0.001) for isolate E4
than the irp2-gene knockout in NB treated with 1% Chelex
containing 0.54 mg/mL 80% iron-saturated lactoferrin as the
main iron source (Figure 2B). This effect was abolished when iron-
saturated lactoferrin was replaced with unsaturated lactoferrin.
These results indicate that a strain with a functional HPI can
obtain iron from saturated lactoferrin in the absence of free iron.
No advantage for the E4 isolate compared to the knockout strain
was observed in media containing either hemin or holo-transferrin
as the main iron source (Figure 2C–D).
Yersiniabactin Inhibits the ROS Response of Human
PMNs
As our hypothesis is that the ROS response of PMNs is
dependent upon iron from lactoferrin, the effect of yersiniabactin
on the ROS response was investigated. ROS production by PMNs
following 4-b-phorobol-12-myristate-13-acetate (PMA) stimulation
was inhibited in a concentration-dependent manner by unsatu-
rated yersiniabactin, while iron-saturated yersiniabactin did not
reduce ROS production by PMNs (Figure 3A, B).
The yersiniabactin-mediated inhibition of ROS production was
reduced by the addition of unsaturated lactoferrin or holo-
transferrin (Figure 3C). The results obtained with iron-saturated
lactoferrin and apo-transferrin were comparable to those obtained
with yersiniabactin (Figure 3D). These results demonstrate that the
yersiniabactin-mediated repression of the ROS response of PMNs
can be released by making iron available to the PMNs.
Yersiniabactin Is Highly Effective Compared to Other
Siderophores
The effect of other siderophores on the reduction of the ROS
response was examined. Yersiniabactin reduced ROS production
more than aerobactin, which is also a known virulence factor in
Enterobacteriaceae (Figure 4). Therapeutic iron chelators, such as
deferoxamine and deferiprone, reduced the ROS production,
but appeared to be less effective than yersiniabactin. Higher
concentrations of deferiprone were also tested because deferiprone
binds iron at a ratio of 1 iron to 3 deferiprone molecules, while the
other tested iron chelators bind iron at 1:1 ratio; however, the
reduction of ROS production by 270 mM deferiprone was still less
than the reduction following treatment with 90 mM yersiniabactin.
When N-Formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP),
rather than PMA, was used to stimulate the PMNs, similar results
were observed (data not shown).
Yersiniabactin Inhibits ROS Response of Human PBMCs
and the Mouse Macrophage Cell Line J774.A1
Yersiniabactin significantly reduced the ROS production of
PMA-stimulated monocytes (Figure 5A), while the reduction of the
ROS production by iron-saturated yersiniabactin was not
significant. Ten to twenty percent of the isolated peripheral blood
mononuclear cells (PBMCs) were monocytes, which indicates that
for each experiment the number of monocytes varied from 1610
5
to 2610
5.
No measurable ROS were produced by the human macro-
phage-like cell lines U937 and THP-1 [36,37] following activation
Yersiniabactin Reduces ROS
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produced ROS following stimulation with PMA[38]. Further-
more, the production of ROS by PMA-stimulated J774.A1 cells
was reduced by all iron chelators tested: yersiniabactin, aerobactin,
deferoxamine, and deferiprone; however, as before, the ROS
production was most strongly inhibited by yersiniabactin
(Figure 5B). Importantly, no cytotoxicity was observed for any of
the tested iron chelators (90 mM) against PMNs, PBMCs, or
J774A.1 cells (data not shown).
Discussion
The yersiniabactin iron uptake system encoded by the HPI is a
known virulence factor of Y. pestis and other Enterobacteriaceae. The
siderophore produced by Enterobacteriaceae, yersiniabactin, is a
highly effective iron chelator that provides iron to the bacteria
during infection. In this study we demonstrate that the growth of a
yersiniabactin-producing strain of E. hormaechei was enhanced
compared to a knockout strain in which the yersiniabactin
production was disrupted in medium where iron-saturated
lactoferrin is the main iron source. In media with hemin or
holo-transferrin as the main iron source, yersiniabactin provided
no additional benefit, probably because the tested strain, E.
hormaechei, contains additional iron uptake systems.
Because it has been suggested that iron is important in the
production of ROS, we investigated if yersiniabactin and other
iron chelators influenced the production of ROS.
Yersiniabactin and other iron chelators reduced ROS produc-
tion in PMNs, monocytes, and a mouse macrophage cell-line
(J774A.1), which suggests that the decreased amount of iron
available for the PMNs was responsible for the reduced ROS
production. This is likely due to competitive binding for iron
between yersiniabactin and iron-binding proteins produced by
mammals. However, as yersiniabactin is a more effective iron
chelator than lactoferrin or transferrin, the equilibrium is in favor
of yersiniabactin, thereby blocking the iron supply to cells of the
innate immune system. The connection between reduced iron
uptake and reduced production of ROS by PMNs has been
previously shown for deferoxamine and deferiprone [35,39].
However, this also suggests that iron is necessary for the majority
of ROS production by PMNs, monocytes, and macrophages. This
also suggests that the Haber-Weiss reaction occurs and that
hydroxyl radicals are formed after activation of these innate
immune cells. Clearly, innate immune cells (PMNs, monocytes,
and macrophages) produce endogenous hydroxyl radicals.
Myeloperoxidase catalyzes the conversion of hydrogen peroxide
to hypochlorous acid (HOCl), which is thought to be the primary
compound responsible for oxidative killing [30]. Surprisingly,
Figure 1. In the irp2 knockout strain the production of yersiniabactin is blocked. Yersiniabactin production was tested using a GFP reporter
assay with the knockout strain WA-CS irp1::Kan
r containing the pCJG3.3N plasmid as the reporter strain to detect yersiniabactin in supernatants. The
number of bacteria versus the measured arbitrary amount of fluorescence from 50,000 counted bacteria is shown in panel A. A) Supernatants from
the irp2 knockout (E4Dirp2) cultures (grey) induced a lower amount of GFP compared to supernatants from the wild-type (WT) cultures (white). This
indicates that production of yersiniabactin was blocked in the irp2 knockout. The experiments were performed in duplicate. B) The GFP reporter assay
is dependent on yersiniabactin production, and production of yersiniabactin in the irp2 knockout is blocked. Yersiniabactin production is only seen in
the wild-type (WT) cells cultured in iron-depleted medium (NBD), while the irp2 knockout (E4Dirp2) strain cultured in NBD and iron-containing
medium (NB), as well as the wild-type strain grown in NB, did not produce yersiniabactin. Three different experiments were performed, with each
sample analyzed in duplicate. C) The expression of HMWP1 and HMWP2 is disrupted by the insertion of a kanamycin resistance gene into irp2 using
the Tagetron Knockout System. The irp2 knockout (E4Dirp2) strain was not able to produce HMWP1 and HMWP2 when cultured in NBD. M: marker;
lane 1: wild-type strain E4; lane 2–5: irp2 gene knockouts created using the wild-type strain E4; lane 6 wild-type EHOS strain 03-702; lane 7: wild-type
EHOS strain 03-819 served as HPI-positive control because the HMWP2 of this strain was confirmed by Edman degradation.
doi:10.1371/journal.pone.0008240.g001
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ity to bacterial infections [30]; the endogenous production of
hydroxyl radicals by innate immune cells could potentially explain
this observation.
Several siderophores were tested: yersiniabactin, aerobactin,
deferoxamine, as well as the iron-chelator deferiprone. Among
these, yersiniabactin was the most effective in reducing ROS
production by human PMNs, human monocytes, and the mouse
macrophage-like cell-line J774.1A. Clearly, yersiniabactin is highly
effective in reducing the innate immune responses of the host.
Previous studies have shown that the presence of HPI increased the
virulence of E. coli and Yersinia species in mice [4,12,13,40]. In both
a mouse bubonic model and a primary pneumonic mouse model,
bacterial genes involved in the detoxification of ROS were down-
regulated, indicating no ROS response targeted the bacteria. In
contrast, the expression of yersiniabactin-iron uptake-system genes
were strongly up-regulated [41,42]. These results, combined with
the results presented in this study, suggest that yersiniabactin
reducesROSproduction,most likelyhydroxyl radical productionin
particular, in innate immune cells both in vitro and in vivo.
Clearly, ROS production, an effective killing mechanism of cells
of the innate immune system [30], is inhibited by yersiniabactin.
The effect of aerobactin, another siderophore produced by
Enterobacteriaceae, is limited in its capability to reduce ROS
production by PMN, monocytes, and mouse macrophages. This
difference can be partly explained by the fact that yersiniabactin
has a much higher affinity for iron than aerobactin (yersiniabactin,
,4610
36 M
21 and aerobactin,1610
23 M
21)[43,44].
Furthermore, we demonstrated that yersiniabactin is more
effective than known and therapeutically used iron chelators, such
as deferoxamine and deferiprone, in reducing ROS production by
PMNs, monocytes, and mouse macrophages. Similar to aero-
bactin, both deferoxamine and deferiprone have a lower affinity
for iron than yersiniabactin (deferoxamine, ,1610
30.6 M
21 and
deferiprone, ,1610
19 M
21 [45,46]). However, in addition to the
iron-binding capacity, other factors (e.g., lipophilicity, pH stability,
and solubility) may play a role. For example, enterobactin has a
very high iron affinity (1.10
52 M
21); however, its role in iron
binding during infections is questionable because its solubility is
very limited in aquatic solutions [43]. Furthermore, siderophores
can be inhibited by lipocalin 2, which is a component of the innate
immune system that limits bacterial growth by sequestering
siderophores [47]. However, based on the resemblance of the
yersiniabactin structure to the siderophore pyochelin, it is unlikely
that yersiniabactin is bound by lipocalin 2 [34]. Clearly, the results
presented here demonstrate that yersiniabactin is the most
effective of the investigated siderophores in reducing ROS
production under physiological conditions.
This suggests that yersiniabactin, or derivates of it, may be good
candidates not only for the treatment of iron overload diseases,
Figure 2. Growth curves of the EHOS E4 isolate and its corresponding irp2 knockout strain. The results are presented as the mean of
three experiments performed in duplicate on different days. Cells were grown in: A) nutrient broth treated with 1% Chelex; B) nutrient broth treated
with 1% Chelex and supplemented with 80% iron-saturated lactoferrin (,6.2 mM, Fe-LF) or unsaturated lactoferrin (,6.4 mM,0-LF); C) nutrient broth
treated with 1% Chelex and supplemented with 17 mM holo-transferrin or 17 mM apo-transferrin; D) nutrient broth treated with 1% Chelex and
supplemented with 10 mMo r3 0mM hemin.
doi:10.1371/journal.pone.0008240.g002
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stress in chronic immune-related diseases, such as asthma or
chronic obstructive pulmonary disease (COPD) [48]. In addition,
many degenerative diseases have been correlated with altered
ROS production [49]. Therefore, yersiniabactin may be also
useful in reducing the progression of these degenerative diseases,
such as Alzheimer’s disease and spinal muscular atrophy [49,50].
Furthermore, vascular diseases and type 2 diabetes have also been
shown to have a relationship with ROS production, and
yersiniabactin may also be able to attenuate the development
and progression of these diseases [51]. However, a possible
drawback for therapeutic use of yersiniabactin is that it may
induce infections with bacteria that are able to take up iron-
saturated yersiniabactin, as has already been shown for deferox-
amine [35,52,53]. Additionally, as deferoxamine has also been
shown to have immunosuppressive effects on T cells [54], which is
mainly mediated through iron sequestering, yersiniabactin may
also have immunosuppressive qualities.
In conclusion, even compared to lactoferrin, the mammalian
protein that binds iron most strongly, the equilibrium for iron
binding is in favor of yersiniabactin. Therefore, yersiniabactin not
only provides bacteria with iron during infection, but also reduces
the iron supply to cells of the innate immune system. Therefore,
little or no iron is available for cells of the innate immune system,
which need iron to produce hydroxyl radicals via the Haber-Weiss
reaction. While it is controversial if the Haber-Weiss reaction takes
place under physiological conditions, the fact that all tested iron
chelators reduce, at least to some extent, ROS production in
Figure 3. ROS production by PMNs is reduced by yersiniabactin. To determine the effect of yersiniabactin on the ROS production of PMNs,
PMNs were pre-incubated with yersiniabactin. PMNs were then activated by PMA, and the production of ROS was measured using luminol. A)
Absolute ROS production measured in arbitrary fluorescence units (A.U.) of PMNs after pre-incubation with yersiniabactin or iron-saturated
yersiniabactin or the controls (PMNs that were only pre-incubated in RPMI/HSA medium and PMNs that were pre-incubated with yersiniabactin but
not stimulated with PMA). B) The yersiniabactin-mediated inhibition of ROS production by PMNs is concentration dependent. Red line: the
concentration-dependent decrease in production of ROS following treatment with yersiniabactin. Blue line: no decrease in ROS production following
treatment with different concentrations of iron-saturated yersiniabactin. Black dotted line: negative control (PMNs incubated with yersiniabactin, but
not stimulated with PMA); ***p value,0.0005, **p value,0.005, *p value,0.05. C) Treatment of PMNs with unsaturated lactoferrin or holo-transferrin
partly inhibits the yersiniabactin-mediated inhibition of ROS production. Black bars: relative ROS production following treatment with yersiniabactin;
gray bars: relative ROS production following treatment with yersiniabactin and unsaturated lactoferrin; white bars: relative ROS production following
treatment with yersiniabactin and holo-transferrin.
aConcentration of the iron chelator. D) Treatment of PMNs with saturated lactoferrin or apo-
transferrin partly inhibits the yersiniabactin-mediated inhibition of ROS production. Black bars: relative ROS production following treatment with
yersiniabactin; gray bars: relative ROS production following treatment with yersiniabactin and saturated lactoferrin; white bars: relative ROS
production following treatment with yersiniabactin and apo-transferrin. All experiments were replicated three times, and each sample was analyzed
in duplicate.
doi:10.1371/journal.pone.0008240.g003
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reaction can take place under physiological conditions. The
reduced production of hydroxyl radicals would result in the
decreased killing of bacteria by innate immune cells, thereby
increasing the likelihood that yersiniabactin-producing Enterobac-
teriaceae, like the EHOS, would cause systemic infections.
Therefore, we hypothesize that the increased virulence of HPI-
positive Enterobacteriaceae is caused by yersiniabactin, which in
addition to improving bacterial growth, also hampers ROS
production in activated innate immune cells. The increased
pathogenicity of the high-pathogenicity group of Yersinia compared
to the low-pathogenicity group and the non-pathogenic group can
be explained by the fact that yersiniabactin, which is only
produced by the high-pathogenicity group, not only provides iron
to the bacterium that is normally bound to iron-binding proteins
produced by mammals, like lactoferrin, but more importantly,
prevents ROS production by innate immune cells
Materials and Methods
Construction of the irp2 Knockout Strain
To determine the role of the HPI in iron uptake, an irp2
knockout strain was generated from the pQC-negative Enterobacter
hormaechei outbreak strain E4 using the TargeTron knockout
system (Sigma-Aldrich, St. Louis, MO, USA). This system inserts a
kanamycin gene into the gene of interest, thereby disrupting its
function. The manufacturer’s protocol was followed, with some
adaptations. In short, a blaMIR-1 promoter was introduced in front
of the intron RNA to replace the T7 promoter using PCR. This
modified pACD4K-C vector was transformed by heat-shock into
competent E. coli DH5ß. The transferred vector was checked by
DNA sequencing. The constructed plasmid was then transformed
Figure 4. Other iron chelators also reduce ROS production by
PMNs. Along with yersiniabactin, aerobactin, deferoxamine, and
deferiprone also reduce ROS production by PMNs. To determine the
effect of other iron-binding molecules on ROS production by PMNs,
PMNs were pre-incubated with aerobactin, deferoxamine, deferiprone,
or yersiniabactin. The pre-treated PMNs were then activated using PMA,
and the production of ROS was measured using luminol. Red line: the
concentration-dependent decrease in ROS production following
yersiniabactin treatment. Gray line: the decrease in ROS production
following treatment with aerobactin. Yellow line: the concentration-
dependent decrease in ROS production following deferiprone treat-
ment. Green line: the concentration-dependent decrease in ROS
production following deferoxamine treatment. The level of ROS
produced by stimulated PMNs without additives was set as 100%.
All experiments were replicated three times, and each sample was
analyzed in duplicate.
doi:10.1371/journal.pone.0008240.g004
Figure 5. ROS production by PBMC-derived monocytes and in the J774A.1 cell line (mouse macrophages) is also reduced by
pre-incubation with iron-binding molecules. A) ROS production in PBMC-derived monocytes pre-incubated with yersiniabactin or iron-
saturated yersiniabactin. Black bars: PBMCs pre-incubated with 90 mM yersiniabactin and subsequently activated with PMA. Gray bar: PBMCs pre-
incubated with 90 mM iron-saturated yersiniabactin and subsequently activated with PMA. White bar: no compounds added.
aBar: Negative control:
90 mM yersiniabactin was added but the cells were not stimulated with PMA; **p value=0.0053, *p value=0.02. B) Yersiniabactin, aerobactin,
deferoxamine, and deferiprone all inhibit ROS production in the J774A.1cell line (mouse macrophages) in a concentration-dependent manner, but
yersiniabactin is the most potent in reducing ROS production. Red line: concentration-dependent decrease in ROS production following treatment
with yersiniabactin. Blue line: concentration-dependent decrease in ROS production following treatment with iron-saturated yersiniabactin. Gray line:
concentration-dependent decrease in ROS production following treatment with aerobactin. Yellow line: concentration-dependent decrease in ROS
production following treatment with deferiprone. Green line: concentration-dependent decrease in ROS production following treatment with
deferoxamine. The level produced by stimulated PMNs without additives was set as 100%. All experiments were replicated three times, and each
sample was analyzed in duplicate.
doi:10.1371/journal.pone.0008240.g005
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selection of possible transformants, the isolates were checked for
the correct insertion of the kanamycin resistance gene into the irp2
gene by DNA sequencing. A GFP assay and SDS-PAGE were
performed to determine whether production of yersiniabactin and
HMWP1 and HMWP2, respectively, were blocked.
HMWP1 and HMWP 2 Expression
To test the functionality of the HPI iron uptake system, the
expression of HMWP1 and HMWP2 were monitored under
various conditions using SDS-PAGE. Bacteria were grown in M9
minimal medium containing 60 mM Na2HPO4,2 2 m M
KH2PO4, 8.6 mM NaCl, 2 mM MgSO4, 0.1 mM CaCl2, 2 g/L
glucose, and 5 g/L casamino acids (pH 7.4) (M9) and in iron-
depleted M9. Iron was depleted with 1% Chelex-100 for 48 h at
37uC followed by the addition of 0.5 mM a,a9-dipyridyl (Sigma-
Aldrich). Proteins were extracted using sonication followed by
centrifugation at 50,0006g for 1 h at 4uC. The pellet was
incubated for 1 h in 2 mL 1% SDS and then centrifuged at
50,0006g for 1 h at 4uC [55]. Subsequently, the supernatant was
concentrated using a Centricon RC-YM 100 2-mL centrifugal
filter (Millipore, Billerica, MA, US). Proteins were separated using
7.5% SDS-PAGE at 40 mA for 1 h, as described by Laemmli et
al. [56]. The gel was stained with Coomassie Blue R. To confirm
the identity of HMWP2, the proteins in the gel were electro-
blotted onto a Immobilon-p Transfer Membrane (Millipore). The
membrane was stained with Coomassie Blue R, and the suspected
HMWP2 band was cut out and sequenced using Edman
degradation (the Sequence Center, Utrecht, The Netherlands).
Yersiniabactin Green Fluorescent Protein (GFP) Reporter
Assay
To test the expression of the iron uptake system, yersiniabactin
production was tested using a GFP-reporter assay [2,40,57]. The
presence of yersiniabactin in the medium can be determined by
measuring the production of GFP because 267 amino acids of
FyuA were fused with GFP, and FyuA is upregulated in the
presence of yersiniabactin. The knockout strain Yersinia enterocolitica
WA-CS irp1::Kan
r, which contains the pCJG3.3N plasmid, (kindly
provided by Prof. J. Heesemann and Dr. S. Schubert) was used as
the reporter strain to detect yersiniabactin in supernatants.
Tested isolates were cultured for seven days at 37uC under
continuous shaking at 150 rpm ineither 10 mlNutrient Broth (NB),
Difco nutrient broth (Becton Dickinson, Sparks, MD, USA) with
85.6 mM NaCl or 10 ml NB with 200 mM a,a9-dipyridyl (NBD).
The supernatant was filtered, and 450 ml was added to 50 mlo fa
culture of the reporter strain WA-CS irp1::Kan
r containing the
pCJG3.3N plasmid. This culture was grown at 28uC overnight in
10 ml NB with 200 mM a,a9-dipyridyl (NBD). The culture was then
centrifuged, and the cells were resuspended to an optical density of
0.1 at 660 nm. When the tested supernatant contains yersiniabac-
tin, GFP production will be induced the reporter strain that encodes
the fyuA-gfp fusion construct, which is induced by yersiniabactin.
The cultures with the GFP strain wereincubated at 28uC overnight,
washed, and diluted in phosphate buffered saline (PBS). The
bacteria-associated fluorescence and scatter data for 50,000 gated
bacteria were measured using flow cytometry (FACSCalibur,
Becton Dickinson, Franklin Lanes, NJ, USA), and the mean
fluorescence was determined.
Growth During Iron Depletion
To test the hypothesis that competitive binding for iron occurs
between yersiniabactin and other iron binding (or containing)
proteins in low iron environments, the growth of the EHOS strain
(E4) and its irp2 gene knockout in different media was compared.
NB was depleted of iron using a 1% Chelex treatment for 2 h
(NBC). To obtain growth curves approximately 10
7 cfu/mL
EHOS E4 and the irp2-knockout were cultured in NBC
supplemented with 0.54 mg/mL (,6.2 mM) 80% saturated
lactoferrin, 0.50 mg/mL (,6.4 mM) unsaturated lactoferrin,
17 mM apo-transferrin, 17 mM holo-transferrin, 10 mM hemin,
or 30 mM hemin (all Sigma-Aldrich) at 37uC under continuous
shaking. The optical density at 600 nm was automatically
measured every 20 min using a Bioscreen C MBR, an automated
microbiology growth analysis system, according to the manufac-
turer’s guidelines (Oy Growth Curves Ab, Helsinki, Finland). The
data for each growth curve were subsequently natural log
transformed. The slope of the exponential growth phase and the
mean value of the stationary phase were determined using
GraphPad Prism version 5.00 (GraphPad Software, San Diego,
CA, U.S.). A paired t-test was then performed to compare the
slopes and the mean values of the stationary phases from the
different cultures [58].
Isolation of Polymorphonuclear Leucocytes and Blood
Mononuclear Cells (PBMCs)
Human PMNs and PBMCs used were isolated using a Ficoll-
Histopaque gradient [59]. The percentage of monocytes
in the PBMC fraction was determined using flow cytometry
(FACSCalibur).
ROS Production
To determine whether the ROS response of innate immune
cells is affected by the presence of yersiniabactin or other iron-
binding compounds, a chemiluminescence assay was used. First,
1610
5 PMNs were pre-incubated with the compound(s) of
interest for 20 min at 37uC. The compounds used were:
yersiniabactin, iron-saturated yersiniabactin, aerobactin (all
Genaxxon BioScience GmbH, Biberach, Germany), deferox-
a m i n em e s y l a t e( N o v a r t i s ,A r nhem, The Netherlands), defer-
iprone (Duchefa Biochemie, Haarlem, The Netherlands), and
iron-saturated and unsaturated lactoferrin and apo- and holo-
transferrin. The reaction was placed in an LB 960 Microplate
Luminometer Centro (Berthold Technologies, Bad Wildbad,
Germany). Automatically, 0.2 mM 5-amino-2,3-dihydro-1,4-
phthalazinedione (Luminol, Sigma-Aldrich) was added (final
concentration 100 nM). After the first read, the PMNs were
activated with PMA (Sigma-Aldrich). Following activation, the
luminescence was measured for 0.3 sec every 50 sec over the
course of 1 h. The area under the curve (AUC) was calculated
using GraphPad Prism version 5.00. The results of each
experiment were standardized by setting the AUC of PMNs
without additives, but stimulated with PMA, as 100% ROS
production.
To determine whether fresh human monocytes or mouse
m a c r o p h a g e sw e r ea b l et op r o d u ce hydroxyl radicals via the
Haber-Weiss reaction and if yersiniabactin was able to reduce
this response, the chemiluminescence assay was also performed
with human PBMCs, human macrophage-like cell lines (U937
and THP-1), and a mouse macrophages cell line (J774A.1;
ATCC TIB67) with some modifications [36–38]: the pre-
incubation time was extended to 2 h, and the measurements
were performed every 2 min for 2 sec over the course of 1 h for
the human PBMCs and over the course of 1.5 h for the tested cell
lines. All experiments were performed in duplicate and repeated
three times.
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